Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus
글루코실세라마이드 합성효소 억제제는 SARS-CoV-2 및 인플루엔자 바이러스의 복제를 방지합니다
Accelerated Communication
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
analogue
antiviral drugs
Antiviral effect
antiviral therapies
breath
caused
CC50, cytotoxicity concentration 50%
cell membranes
Cerdelga
clinical trials
component
coronavirus
COVID-19
COVID-19 pandemic
CPE, cytopathic effect
creating
cross
DENV, dengue virus
dependency
disrupt
DMSO, dimethyl sulfoxide
DNJ, deoxynojirimycin
drug
Drug administration
DsiRNA, Dicer-substrate siRNA
examined
food
GCS, glucosylceramide synthase
GlcCer, glucosylceramide
global health
glucosylceramide
glucosylceramide synthase
GZ-161, GENZ-667161
GZ-346, Genz-123346
H1N1
Health
host cell
host cell membrane
host cell membranes
Infection
Influenza
Influenza virus
inhibit
inhibitor
life cycle
life cycles
limit
LSD, lysosomal storage disease
MDCK, Madin–Darby Canine Kidney
membrane
MOI, multiplicity of infection
NB-DNJ, N-butyl–DNJ
not applicable
outcomes
Phase III clinical trials
PR8, influenza virus A/PR/8/34 (H1N1)
Prevent
Replication
replication of SARS-CoV-2
respiratory
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
severe acute respiratory syndrome Coronavirus
SI, selective index
specific inhibitor
specific inhibitors
sphingolipids
Support
synthesis
the United State
therapeutic target
Treatment
United States
Vaccine
venglustat
Viral
viral life cycle
virus
viruses
[DOI] 10.1016/j.jbc.2021.100470 PMC 바로가기 [Article Type] Accelerated Communication
[DOI] 10.1016/j.jbc.2021.100470 PMC 바로가기 [Article Type] Accelerated Communication